NDA 050821 · B Braun
Cefepime and Dextrose In Duplex Container
Cefepime Hydrochloride · Injection
Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
May 6, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
78
22 Phase 3, 8 recruiting
FAERS reports
1,805
1,700 serious, 459 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 7, 2026.
Cefepime for Injection and Dextrose Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia ( 1.1 ) Empiric therapy for febrile neutropenic patients ( 1.2 ) Uncomplicated and complicated urinary tract infections ( 1.3 ) Uncomplicated skin and skin structure infections ( 1.4 ) Complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and Dextrose Injection and other antibacterial drugs, Cefepime for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime for Injection and Dextrose Injection is indicated for the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae (including cases associated with concurrent bacteremia), Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime for Injection and Dextrose Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see Clinical Studies (14.1) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime for...
Mechanism: Cefepime is a cephalosporin antibacterial drug [see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER · CEFEPIME HYDROCHLORIDE EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription
- CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER · CEFEPIME HYDROCHLORIDE EQ 2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cefepime" as an intervention, any sponsor and status, largest first.
- Effect of Antibiotic Choice On ReNal Outcomes (ACORN)Pivotal-lookingCompleted
Vanderbilt University Medical CenterAcademic, hospital or other
NCT05094154 · 2,634 participants · Start Nov 10, 2021 · Primary completion Oct 21, 2022
Drug: anti-pseudomonal cephalosporin; anti-pseudomonal penicillin · For: Sepsis; AKI; Neurotoxicity
Sites: Nashville, Tennessee
- Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract InfectionsPivotal-lookingCompleted
AllecraIndustry
NCT03687255 · 1,043 participants · Start Sep 24, 2018 · Primary completion Jan 30, 2020
Drug: cefepime/AAI101 combination; Piperacillin/tazobactam · For: Urinary Tract Infections
Sites: Anaheim, California; Buena Park, California; Tampa, Florida · 24 sites in all
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy TrialPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06080698 · 1,030 participants (planned) · Start Feb 22, 2024 · Primary completion May 31, 2027
Drug: Intravenous Antibiotics; Oral Antibiotics · For: Gram-negative Bacteremia
Sites: San Francisco, California; Denver, Colorado; Baltimore, Maryland · 11 sites in all
- Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)Pivotal-lookingStatus unknown
WockhardtIndustry
NCT03630081 · 1,004 participants (planned) · Start Jan 2024 · Primary completion Jan 2026
Drug: WCK 4282 (FEP-TAZ) 4 g; Meropenem and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis
- Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. AeruginosaPivotal-lookingCompleted
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian FederationAcademic, hospital or other
NCT03638830 · 777 participants · Start Oct 17, 2018 · Primary completion Nov 23, 2022
Drug: Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim; Ftortiazinon (tablets 300 mg) full dose + Maxipim · For: Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa; Pseudomonas Aeruginosa; Pseudomonas Infections and 1 more
Sites: Saint Petersburg, Russia; Vsevolozhsk, Russia · 5 sites in all
- A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized PatientsPivotal-lookingRecruiting
University of PennsylvaniaAcademic, hospital or other
NCT06954129 · 750 participants (planned) · Start Jan 28, 2026 · Primary completion May 2029
Drug: Vancomycin; Piperacillin-tazobactam and 1 more · For: Acute Kidney Injury
Sites: Philadelphia, Pennsylvania
- Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract InfectionsPivotal-lookingCompleted
Venatorx Pharmaceuticals, Inc.Industry
NCT03840148 · 661 participants · Start Aug 7, 2019 · Primary completion Dec 14, 2021
Drug: Cefepime/VNRX-5133 (taniborbactam); Meropenem · For: Urinary Tract Infections; Acute Pyelonephritis
Sites: Buena Park, California; Chula Vista, California; La Mesa, California · 78 sites in all
- Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated PyelonephritisPivotal-lookingCompleted
Meiji Seika Pharma Co., Ltd.Industry
NCT05887908 · 614 participants · Start May 23, 2023 · Primary completion Nov 22, 2024
Drug: co-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis; cUTI and 1 more
Sites: Pleven, Bulgaria; Rousse, Bulgaria; Silistra, Bulgaria · 61 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- febrile neutropenia192
- pyrexia191
- pneumonia138
- acute kidney injury105
- drug ineffective100
- off label use87
- platelet count decreased77
- anaemia74
- neutrophil count decreased73
- neutropenia72
- rash72
- diarrhoea68
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 6 |
| 2006 | 8 |
| 2007 | 5 |
| 2008 | 14 |
| 2009 | 13 |
| 2010 | 24 |
| 2011 | 74 |
| 2012 | 68 |
| 2013 | 40 |
| 2014 | 33 |
| 2015 | 40 |
| 2016 | 42 |
| 2017 | 32 |
| 2018 | 65 |
| 2019 | 90 |
| 2020 | 93 |
| 2021 | 144 |
| 2022 | 218 |
| 2023 | 264 |
| 2024 | 230 |
| 2025 | 182 |
| 2026 | 114 |
Recalls
2 FDA enforcement reports for this application.
Nov 21, 2013 · Class I · Terminated
Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.
Oct 15, 2013 · Class I · Terminated
Presence of Particulate Matter: The 1g Cefepime for Injection USP and Dextrose Injection USP lot has been found to contain visible organic particulate matter in a reserve sample unit.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cefepime-induced neurotoxicity: a systematic review.
Payne LE, Gagnon DJ, Riker RR, et al. · Crit Care 2017 · Systematic Review
- Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis.
Wagenlehner F, Caballero VR, Maheshwari V, et al. · J Comp Eff Res 2025 · Systematic Review, Network Meta-Analysis
- Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W, Deng T, Li S, et al. · BMC Infect Dis 2023 · Systematic Review, Network Meta-Analysis
- Cefepime-induced neurotoxicity: systematic review.
Maan G, Keitoku K, Kimura N, et al. · J Antimicrob Chemother 2022 · Systematic Review
- Vancomycin combined with piperacillin/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis.
Pan K, Li R, Li Y, et al. · J Antimicrob Chemother 2025 · Systematic Review, Network Meta-Analysis
- Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
Kaye KS, Belley A, Barth P, et al. · JAMA 2022 · Clinical Trial, Phase III, Comparative Study
Sponsor: B Braun
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.